title: The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.
abstract: BACKGROUND
  We have previously reported that selective antagonism of brain D3 receptors by SB-277011A or NGB 2904 significantly attenuates cocaine- or nicotine-enhanced brain stimulation reward (BSR).
  
  
  OBJECTIVE
  In the present study, we investigated whether the selective D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 agonist BP-897 similarly reduce methamphetamine (METH)-enhanced BSR.
  
  
  METHODS
  Rats were trained to respond for rewarding electrical self-stimulation of the medial forebrain bundle. To assess the degree of drug-induced changes in BSR, a rate-frequency curve shift paradigm was used to measure brain-reward threshold (theta 0).
  
  
  RESULTS
  METH (0.1-0.65 mg/kg, i.p.) dose-dependently lowered ( approximately 10-50%) BSR thresholds, producing an enhancement of BSR. Pretreatment with SB-277011A (12 mg/kg, but not 24 mg/kg, i.p.) significantly attenuated METH-enhanced BSR. NGB 2904 (0.1-1.0 mg/kg, but not 10 mg/kg) also attenuated METH-enhanced BSR. SB-277011A or NGB 2904 alone, at the doses tested, had no effect on BSR. Pretreatment with BP-897 (0.1-5 mg/kg) dose-dependently attenuated METH-enhanced BSR. However, when the dose was increased to 10 mg/kg, BP-897 shifted the stimulation-response curve to the right (inhibited BSR itself) in the presence or absence of METH.
  
  
  CONCLUSIONS
  Selective antagonism of D3 receptors by SB-277011A or NGB 2904 attenuates METH-enhanced BSR in rats, while the METH-enhanced BSR attenuation produced by BP-897 may involve both D3 and non-D3 receptors. These findings support a potential use of selective D3 receptor antagonists for the treatment of METH addiction.
authors.affiliation: Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA.
authors.forename: Krista
authors.initials: K
authors.lastname: Spiller
authors.forename: Zheng-Xiong
authors.initials: ZX
authors.lastname: Xi
authors.forename: Xiao-Qing
authors.initials: XQ
authors.lastname: Peng
authors.forename: Amy H
authors.initials: AH
authors.lastname: Newman
authors.forename: Charles R
authors.initials: CR
authors.lastname: Ashby
authors.forename: Christian
authors.initials: C
authors.lastname: Heidbreder
authors.forename: József
authors.initials: J
authors.lastname: Gaál
authors.forename: Eliot L
authors.initials: EL
authors.lastname: Gardner
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005449:Fluorenes / Q000494:pharmacology; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D009570:Nitriles / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D050637:Receptors, Dopamine D3 / Q000819:agonists* / Q000037:antagonists & inhibitors*; D012201:Reward; D044005:Tetrahydroisoquinolines / Q000494:pharmacology
chemical_list: D000697:Central Nervous System Stimulants; D005449:Fluorenes; C116818:NGB 2904; D009570:Nitriles; D010879:Piperazines; D050637:Receptors, Dopamine D3; C409982:SB 277011; D044005:Tetrahydroisoquinolines; C120565:BP 897; D008694:Methamphetamine